Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.61 |
| ▸ | HTR2A | P28223 | 6/20 | 0.61 |
| ▸ | RAB9A | P51151 | 5/20 | 0.55 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | TP53 | P04637 | 4/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.55 |
| ▸ | RELA | Q04206 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2481583 | 0.82 | HTR2A (0.64) | HTR2CHTR2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL14826631 | 0.82 | HTR2C (0.74) | HTR2CHTR2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL13536431 | 0.81 | HTR2C (0.65) | HTR2CHTR2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL14089574 | 0.78 | LMNA (0.71) | RAB9ANPC1SMN1; SMN2TP53NFKB1 | |
| SCHEMBL13190423 | 0.78 | DGAT1 (0.62) | HTR2CHTR2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4866075 | 0.78 | TP53 (0.59) | HTR2CHTR2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL5113702 | 0.77 | ADRB2 (0.56) | HTR2CHTR2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL12372352 | 0.76 | PTPN11 (0.88) | PTPN11 | |
| SCHEMBL4867152 | 0.76 | TP53 (0.64) | HTR2CHTR2ARAB9ANPC1SMN1; SMN2 | |
| SCHEMBL24064690 | 0.75 | HTR2A (0.58) | HTR2CHTR2ARAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541432-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2013-09-24 | — | — | US | disclosed |
| US-8501756-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2013-08-06 | — | — | US | disclosed |
| US-8492393-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2013-07-23 | — | — | US | disclosed |
| US-8486954-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2013-07-16 | — | — | US | disclosed |
| US-8431584-B2 | Heterobicyclic carboxamides as inhibitors for kinases | NOVARTIS AG (CH) | 2013-04-30 | — | — | US | disclosed |
| US-20130012529-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2013-01-10 | — | — | US | disclosed |
| US-20130005750-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2013-01-03 | — | — | US | disclosed |
| US-20130005753-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2013-01-03 | — | — | US | disclosed |
| US-20130005751-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2013-01-03 | — | — | US | disclosed |
| US-20120245187-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005753-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | CDK2, PHKG1, PHKG2 | HTR2C 3215/4885HTR2A 3021/4885RAB9A 2155/4885 |
| US-20120245187-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | CDK2, PHKG1, PHKG2 | HTR2C 3215/4885HTR2A 3021/4885RAB9A 2155/4885 |
| US-20130005751-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | CDK2, PHKG1, PHKG2 | HTR2C 3215/4885HTR2A 3021/4885RAB9A 2155/4885 |
| US-20130005750-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | CDK2, PHKG1, PHKG2 | HTR2C 3215/4885HTR2A 3021/4885RAB9A 2155/4885 |
| US-20130012529-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | CDK2, PHKG1, PHKG2 | HTR2C 3215/4885HTR2A 3021/4885RAB9A 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.